RCS - Solvonis Therapeutic - CSO Speaks at National Research Meeting

Solvonis TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9053Ca&default-theme=true

RNS Number : 9053C  Solvonis Therapeutics PLC  05 May 2026

 

5th May 2026

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

Solvonis Chief Scientific Officer Professor David Nutt to Speak at U.S.
National Institutes of Health Addiction Research Meeting

Professor Nutt to speak on psychedelic therapy for addictions at major U.S.
federal addiction-research forum

Solvonis' Chief Scientific Officer to participate alongside senior leaders
from NIDA, NIAAA and NCI, the principal U.S. federal bodies shaping addiction
research

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, notes that Professor David Nutt, Chief Scientific
Officer of Solvonis, is scheduled to speak at a high-profile public addiction
research meeting convened by the U.S. National Institutes of Health ("NIH").

Professor Nutt is expected to speak on psychedelic therapy for addictions at
the 14th Joint Meeting / 13th CRAN of the National Advisory Council on Alcohol
Abuse and Alcoholism, the National Cancer Advisory Board and the National
Advisory Council on Drug Abuse, taking place on 6 May 2026.

The NIH is the principal medical research agency of the United States
government and the world's largest single public funder of biomedical and
behavioural research, with an annual budget of more than US$47 billion.

CRAN - Collaborative Research on Addiction at NIH - is the NIH partnership
through which the National Institute on Alcohol Abuse and Alcoholism
("NIAAA"), the National Institute on Drug Abuse ("NIDA") and the National
Cancer Institute ("NCI") coordinate research across substance use, misuse,
addiction and related health consequences.

The meeting brings together senior U.S. federal leaders in addiction-related
research, including Dr Nora Volkow, Director of NIDA, and Dr George Koob,
Director of NIAAA. Professor Nutt is the sole external speaker, placing
Solvonis' Chief Scientific Officer in a prominent U.S. forum alongside senior
figures who help shape the U.S. national scientific and funding priorities for
alcohol, drug-use and addiction-related disorders.

Relevance to Solvonis

For UK investors, the relevance is clear. Solvonis is a London-listed CNS
biopharmaceutical company focused on high-burden addiction and psychiatric
disorders, operating in therapeutic areas attracting increasing scientific,
policy and commercial attention in the United States and globally.

NIDA and NIAAA are among the most influential addiction-research institutions
in the world. Published U.S. budget materials show the scale of these
organisations, with NIDA's FY2025 budget request at approximately US$1.67
billion and NIAAA's FY2025 appropriation at approximately US$595 million.

Professor Nutt's participation highlights the calibre, relevance and
international profile of Solvonis' scientific leadership. His expected
presentation on psychedelic therapy for addictions is directly relevant to the
field in which Solvonis is developing its addiction-focused pipeline:
innovative CNS pharmacology combined, where appropriate, with structured
psychosocial support.

Solvonis' addiction-focused pipeline includes:

·    SVN-001, the Company's late-stage ketamine-assisted therapy programme
for severe Alcohol Use Disorder, currently being evaluated in a UK Phase 3
study;

·    SVN-002, the Company's U.S.-focused esketamine oral thin film
programme for moderate-to-severe Alcohol Use Disorder, which is being
developed with structured psychosocial support; and

·    SVN-015, the Company's preclinical programme for stimulant-use
disorders, which has been selected for evaluation through the U.S. National
Institute on Drug Abuse's Addiction Treatment Discovery Program.

Together, these programmes position Solvonis across alcohol and substance-use
disorders, with a pipeline spanning late-stage clinical development,
U.S.-focused mid-clinical development and earlier-stage discovery in areas of
significant unmet medical need.

CEO Comment

Anthony Tennyson, Chief Executive Officer of Solvonis, commented:

"This is a high-profile U.S. addiction-research forum convened through the
NIH's cross-institute CRAN initiative, bringing together NIDA, NIAAA and NCI -
the principal U.S. federal bodies active in addiction-related research.

"Professor Nutt's participation as the sole external academic speaker listed
for the public session reflects his international standing in addiction
neuroscience, neuropsychopharmacology and psychedelic-assisted therapy.

"For Solvonis, this is highly relevant. We are a UK-listed CNS
biopharmaceutical company advancing programmes across Alcohol Use Disorder,
addiction and psychiatry, including a NIDA-linked preclinical programme in
stimulant-use disorders.

"This does not imply endorsement of Solvonis or its programmes by NIH, NIDA,
NIAAA or NCI. It does, however, underline that the scientific themes central
to our strategy are being discussed at the highest levels of the U.S.
addiction-research community."

Important Notice

Professor Nutt is listed by NIH in his academic capacity at Imperial College
London. This announcement does not imply endorsement of Solvonis, its
programmes, its product candidates or its development strategy by NIH, NIDA,
NIAAA, NCI or any U.S. government agency.

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

info@solvonis.com

Singer Capital Markets (Broker)

Phil Davies

+44 (0) 20 7496 3000

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

 

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

 

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

 

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKSLEFXKEFA



            Copyright 2019 Regulatory News Service, all rights reserved